Filing Analysis
Minerva Neurosciences reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders approved amendments to the Certificate of Incorporation regarding officer exculpation and forum provisions, and the Board adopted amended and restated bylaws.
📋 Key Facts
- Stockholders approved the 'Exculpation Amendment' to limit liability of certain officers for monetary damages per Delaware law.
- Stockholders approved the 'Exclusive Forum Amendment' to eliminate the exclusive forum provision.
- The Board approved Amended and Restated Bylaws effective June 3, 2026, which include updates to advance notice procedures and universal proxy rule compliance (Rule 14a-19).
- Two directors, Dr. David Kupfer and Jan van Heek, were elected to the Board until the 2029 annual meeting.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders voted for a 1-year frequency for advisory votes on executive compensation.
Minerva Neurosciences entered into an 'at-the-market' (ATM) offering agreement with Leerink Partners LLC to sell up to $75 million in common stock. Additionally, the company announced a revision to the relapse assessment phase of its Phase 3 C19 trial for roluperidone, extending it from 40 to 52 weeks following FDA feedback.
🚩 Red Flags
- Potential for significant shareholder dilution via the $75M ATM facility.
- Clinical trial extension (relapse assessment phase) based on FDA feedback, which increases the time to data and potentially increases costs.
📋 Key Facts
- Entered into ATM offering agreement with Leerink Partners LLC on May 27, 2026.
- Maximum aggregate offering price of ATM shares is $75.0 million.
- Agent (Leerink Partners) receives a commission of 3.0% of gross proceeds.
- Phase 3 C19 trial relapse assessment phase extended from 40 weeks to 52 weeks due to FDA feedback.
- Topline efficacy results for C19 trial expected in H2 2027, with relapse assessment data in H2 2028.
Minerva Neurosciences, Inc. reported its financial results for the first fiscal quarter ended March 31, 2026. The filing is a routine quarterly update furnished to the SEC under Item 2.02.
📋 Key Facts
- The report was filed on May 5, 2026, covering the fiscal quarter ended March 31, 2026.
- The company furnished a press release as Exhibit 99.1 regarding its financial results.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- Minerva Neurosciences is listed on The Nasdaq Capital Market under the ticker NERV.
Minerva Neurosciences announced its 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026. Due to the timing shifting more than 30 days from the prior year's anniversary, the company established new deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting scheduled for June 3, 2026
- Stockholder proposal deadline under Rule 14a-8 set for April 16, 2026
- Director nomination and other business notice deadline set for April 21, 2026
- The meeting date is more than 30 days from the anniversary of the 2025 annual meeting
Minerva Neurosciences announced the resignation of President Geoffrey Race, effective March 31, 2026, and the appointment of James O’Connor as Chief Business Officer and General Counsel. The company entered into a settlement agreement with Mr. Race involving significant severance benefits and a one-year consultancy agreement.
🚩 Red Flags
- Full acceleration of stock option vesting for a departing executive.
- Unusually long extension of the option exercise period until January 1, 2030.
- Immediate transition to a high-rate consultancy role (£333/hour) following resignation.
📋 Key Facts
- Geoffrey Race resigned as President and Director of Mind-NRG SARL effective March 31, 2026.
- Race will receive a one-time payment of his annual salary, 12 months of pension contributions, and a pro-rated 2026 bonus.
- Additional severance includes £30,000, medical/life insurance coverage, and legal fee reimbursement up to £15,000.
- All outstanding stock options for Mr. Race were fully vested as of March 31, 2026, with the exercise period extended to January 1, 2030.
- A consultancy agreement was established with Mr. Race at a rate of £333 per hour for a minimum of 35 hours per month starting April 15, 2026.
- James O’Connor was appointed Chief Business Officer and General Counsel effective April 21, 2026.
Minerva Neurosciences, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to this filing.
📋 Key Facts
- Filing date: March 11, 2026
- Reporting period: Quarter and fiscal year ended December 31, 2025
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- The press release is included as Exhibit 99.1